Osteoporosis Management in Elderly Patients

Assessment of Current Fracture Risk

• The patient's advanced age places her at high risk for osteoporotic fractures, with age being an independent risk factor that significantly elevates fracture risk 3
• BMD scan showing osteoporosis after the drug holiday indicates treatment failure and the need to restart pharmacologic therapy 1, 4
• The American College of Physicians recommends bisphosphonates as first-line therapy for postmenopausal women with osteoporosis due to their favorable balance of benefits, risks, and costs 1, 2

Rationale for Restarting Therapy

• Bisphosphonates reduce the risk of vertebral fractures by approximately 50% over 3 years in high-risk patients 3
• After a drug holiday, if BMD decreases or shows osteoporosis, treatment should be restarted to prevent fractures 5, 4

Treatment Recommendations

• Restart oral alendronate at standard dosing (70mg weekly) as the first-line option 1, 2
• Ensure adequate calcium and vitamin D supplementation alongside bisphosphonate therapy 1, 6

Special Considerations for Elderly Patients

• Consider polypharmacy and potential drug interactions when restarting therapy 5
• Evaluate renal function before restarting, as decreased renal function may affect dosing or choice of agent 6

When to Consider Alternative Therapies

• If the patient has contraindications to bisphosphonates or experiences adverse effects, consider denosumab as a second-line option 1, 6
• For very high-risk patients with multiple fractures, consider anabolic agents followed by antiresorptive therapy 5